You are here: Industry Insights > Zydus

News List

Zydus Recalls Acyclovir Sodium Injection, 50 mg/mL americanpharmaceuticalreview
March 29, 2021
Zydus Pharmaceuticals (USA) Inc. is voluntarily recalling four lots of Acyclovir Sodium Injection, 50 mg/mL, 10 mL and 20 mL vials, to the Hospital/User level after receiving several complaints of crystallization in vials.
Zydus Cadila gets final nod from USFDA for Droxidopa Capsules expresspharma
February 20, 2021
Zydus Cadila has received final approval from the USFDA to market Droxidopa Capsules, 100 mg, 200 mg, and 300 mg (US RLD: Northera Capsules).
Zydus announces completion of Phase-I trials of ZY19489 expresspharma
February 05, 2021
Zydus Cadila announced that its anti-malarial compound ZY19489 (MMV253) in development with Swiss-based product development partnership Medicines for Malaria Venture (MMV) has now completed Phase I clinical evaluation [Reg’n Number ACTRN12619000127101].
Desidustat Shows Efficacy, Safety Treating Hypoxia in Hospitalized COVID-19 Patients americanpharmaceuticalreview
January 29, 2021
Zydus announced it has received positive results from Phase 2(b) studies of Desidustat in COVID-19 patients conducted at Mexico.
Zydus’ Desidustat efficacious in treating hypoxia in Mexico’s hospitalised COVID-19 patients: Study expresspharma
January 25, 2021
None of the hospitalised patients required mechanical ventilator in the Desidustat arm, while 25 per cent patients on the standard of care arm required mechanical ventilator.
Zydus gets DCGI approval for Saroglitazar Mg to treat non-alcoholic fatty liver disease expresspharma
December 31, 2020
Saroglitazar Mg is already approved for the treatment of type-2 diabetes and NASH.
Zydus seeks approval for Phase III clinical trials of ZyCoV-D, submits Phase I/II clinical trial data expresspharma
December 28, 2020
ZyCoV-D was found to be safe, well tolerated and immunogenic in the Phase I/II clinical trials, informs company.
USFDA grants Zydus fast track designation for Saroglitazar to treat primary biliary cholangitis expresspharma
December 10, 2020
Zydus announced that the United States Food and Drug Administration (USFDA) has granted ‘Fast Track Designation’ to Saroglitazar Mg for the treatment of patients with primary biliary cholangitis (PBC).
Zydus announces Phase I trials of ZYIL1, oral small molecule NLRP3 inflammasome inhibitor expresspharma
December 08, 2020
NLRP3 inflammasomes lead to the onset and development of diseases like ARDS, auto-immune diseases, inflammatory diseases, CVDs, metabolic disorders, gastrointestinal diseases, renal diseases and CNS diseases.
Zydus gets DCGI approval to commence Phase III clinical trials with Pegylated Interferon alpha-2b expresspharma
December 07, 2020
In Phase II clinical trials, Pegylated Interferon alpha – 2b increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients.

Previous page 1 2 3 4 5 Next page